# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

**WASHINGTON, DC 20549** 

## FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported) August 8, 2005

# **Nabi Biopharmaceuticals**

(Exact Name of Registrant as Specified in Its Charter)

**Delaware** (State or Other Jurisdiction of Incorporation)

000-04829 (Commission File Number) 59-1212264 (IRS Employer Identification No.)

5800 Park of Commerce Boulevard N.W., Boca Raton, FL (Address of Principal Executive Offices)

02324 (Zip Code)

(561) 989-5800 (Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):	
	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

#### Item 1.02. Termination of Material Definitive Agreement.

On August 8, 2005, Nabi Biopharmaceuticals (the "Company") terminated the employment period without cause under an Employment Agreement with Richard G. Clark, the Company's Senior Vice President, Administration and Chief Administrative Officer. The termination will be effective as of September 7, 2005. Mr. Clark will be entitled to certain severance benefits as a result of this termination subject to and in accordance with the terms of his Employment Agreement.

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

### NABI BIOPHARMACEUTICALS

Date: August 12, 2005 By: /s/ Mark L.Smith

Name: Mark L. Smith

Title: Senior Vice President, Finance, Chief Financial Officer, Chief Accounting Officer,

and Treasurer